STONY BROOK, NY. April 20, 2017 – Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, announced that it has entered into an agreement to supply bulk DNA for a leading chemicals company serving the in vitro diagnostics market. The agreement is for five years with quarterly shipments and includes optional three-year renewals thereafter. The Company expects the agreement to generate annual revenues of approximately $500,000 beginning in FY 2018 with a pro-rated amount expected in FQ4:17.

Applied DNA’s manufacturing technology enables very-large-scale production of bulk DNA using proprietary polymerase chain reaction (PCR) methods. The technology, acquired with the company’s purchase of the assets of Vandalia Research Inc., in 2015, enables custom DNA sequences to be produced in large scale, quicker and cleaner when compared to culture methods of production. Applications for DNA manufactured using Applied DNA’s methods include vaccines, diagnostics, reagents, bio-agriculture, and gene therapies for existing and emerging markets.

“The ability to offer PCR-based DNA production that is more efficient and cost-effective is unique and a significant competitive advantage in the marketplace relative to other bulk DNA production methods,” said Dr. James A. Hayward, president and CEO of Applied DNA. “This long-term supply agreement reflects efforts being made to cross-sell our cutting-edge capabilities to both existing and prospective pharmaceutical and diagnostics customers, opportunities that we believe hold the potential to yield similar, long-term, recurring order-flow. Together with an increasing number of in-bound inquiries from prospective customers that recognize the benefits of PCR-produced DNA in their product, we believe this business should see growth going forward.”

About Applied DNA Sciences

Applied DNA Sciences makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT^TM” platform can be used to identify, tag, track, and trace products, to help assure authenticity, origin, traceability and quality of products. SigNature^® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, BackTrac™and DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track- and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements

The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly report on Form 10-Q filed on February 9, 2017, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Debbie Bailey, 631-240-8817, debbie.bailey@adnas.com
Media contact: Susan Forman, DGIComm., 212-825-3210, sforman@dgicomm.com
Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com